ReviewCNS drugs2026
Opioid Add-On Combination Therapy for Cancer Pain: Pharmacological Rationale, Clinical Evidence, and Future Directions.
Review in CNS drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer-related pain affects up to 66% of patients in advanced stages, and 10-30% experience inadequate relief with single-agent opioid therapy despite dose titration and opioid rotation. The opioid add-on strategy, the deliberate addition of a second opioid at low doses to an ongoing regimen without discontinuing the first agent, has emerged as a promising approach to address this therapeutic gap. This narrative review synthesizes the pharmacological rationale, clinical evidence, safety profile, pharmacogenetic considerations, and guideline positions regarding opioid add-on combination therapy, with particular focus on low-dose methadone (3-15 mg/day) as the add-on agent. Methadone possesses a uniquely multimodal pharmacological profile: its L-isomer is a potent mu/delta opioid receptor agonist, while racemic methadone inhibits N-methyl-D-aspartate receptors at IC50 values 8-16 times lower than morphine, and its D-isomer provides serotonin/norepinephrine reuptake inhibition. Clinical evidence from three randomized controlled trials, multiple prospective and retrospective studies, a network meta-analysis, and a national survey of 410 patients consistently demonstrates responder rates of 50-94%, pain score reductions of 2-3 Numerical Rating Scale points within 7-15 days, and a significant reduction in rescue opioid consumption. The safety profile at low doses appears favourable, with no reported cases of corrected QT interval-related events or respiratory depression, although caution is warranted in patients with survival ≤ 14 days because of increased sedation and delirium risk. Cytochrome P450 2B6 polymorphisms, particularly the 6 variant, represent a potential source of pharmacokinetic variability warranting further investigation. Despite this growing evidence, no major international guideline explicitly addresses the low-dose add-on strategy. Large comparative trials against opioid rotation and pharmacogenetically guided dosing studies are needed to establish the place of this strategy in the cancer pain management algorithm.
Indexed as
Identifiers
42645704What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.